文献速递神经免疫

中枢神经系统脱髓鞘患者亚组中的髓鞘少突胶质细胞糖蛋白免疫球蛋白A抗体

Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项纵向研究纳入5个中心的1339例患者和110例健康对照,检测血清和脑脊液中的MOG-IgA、MOG-IgG和MOG-IgM。在AQP4-IgG和MOG-IgG双阴性患者中,孤立MOG-IgA见于6%的视神经脊髓炎谱系疾病、2%的其他中枢神经系统脱髓鞘疾病和1%的多发性硬化患者,健康对照中未见。MOG-IgA阳性患者最常见表现为脊髓炎,且脑干综合征较MOG-IgG患者更常见,视神经炎较少见。

要点

  • 在AQP4-IgG和MOG-IgG双阴性患者中,孤立MOG-IgA在视神经脊髓炎谱系疾病中占6%(3/50)。
  • 孤立MOG-IgA阳性患者最常见表现为脊髓炎(11/17 [65%])。
  • 与MOG-IgG患者相比,MOG-IgA阳性患者脑干综合征更常见(7/16 [44%] vs 14/75 [19%],P = .048),视神经炎较少见(4/15 [27%] vs 46/73 [63%],P = .02)。

核心结论

  • MOG特异性IgA见于AQP4-IgG和MOG-IgG双阴性患者的一个亚组,提示MOG-IgA可能是中枢神经系统脱髓鞘患者的新型诊断生物标志物。

研究设计与样本

  • 这项纵向研究包含1个发现队列和1个验证队列,来自5个中心,纳入疑似或确诊脱髓鞘疾病患者及健康对照,于2012年9月至2022年4月评估。
  • 排除5例同时存在AQP4-IgA和MOG-IgA、MOG-IgG和/或MOG-IgM的参与者后,最终纳入1339例患者和110例健康对照,中位随访时间为39个月(范围0-227个月)。

主要发现

  • 在AQP4-IgG和MOG-IgG双阴性患者(1126/1339;84%)中,孤立MOG-IgA见于3/50(6%)视神经脊髓炎谱系疾病患者、5/228(2%)其他中枢神经系统脱髓鞘疾病患者和10/848(1%)多发性硬化患者,健康对照中未见(0/110)。
  • 孤立MOG-IgA阳性患者中最常见的疾病表现为脊髓炎(11/17 [65%]),其次为脑干综合征(7/16 [44%] vs 14/75 [19%],P = .048)较MOG-IgG患者更常见,视神经炎较少见(4/15 [27%] vs 46/73 [63%],P = .02)。
  • 在符合2017年McDonald多发性硬化诊断标准的患者中,与MOG-IgG/IgA双阴性多发性硬化患者相比,MOG-IgA与较少见的脑脊液特异性寡克隆带相关(4/9 [44%] vs 325/351 [93%],P < .001)。
  • 大多数孤立MOG-IgA阳性患者在近期感染或疫苗接种后出现临床发作(7/11 [64%])。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Differential diagnosis of patients with seronegative demyelinating central nervous system (CNS) disease is challenging. In this regard, evidence suggests that immunoglobulin (Ig) A plays a role in the pathogenesis of different autoimmune diseases. Yet little is known about the presence and clinical relevance of IgA antibodies against myelin oligodendrocyte glycoprotein (MOG) in CNS demyelination. OBJECTIVE: To investigate the frequency of MOG-IgA and associated clinical features in patients with demyelinating CNS disease and healthy controls. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal study comprised 1 discovery and 1 confirmation cohort derived from 5 centers. Participants included patients with suspected or confirmed demyelinating diseases and healthy controls. MOG-IgA, MOG-IgG, and MOG-IgM were measured in serum samples and cerebrospinal fluid (CSF) of patients, who were assessed from September 2012 to April 2022. MAIN OUTCOMES AND MEASURES: Frequency and clinical features of patients who were seropositive for MOG-IgA and double-seronegative for aquaporin 4 (AQP4) IgG and MOG-IgG. RESULTS: After the exclusion of 5 participants with coexisting AQP4-IgG and MOG-IgA, MOG-IgG, and/or MOG-IgM, 1339 patients and 110 healthy controls were included; the median follow-up time was 39 months (range, 0-227 months). Of included patients with isolated MOG-IgA, 11 of 18 were female (61%), and the median age was 31.5 years (range, 3-76 years). Among patients double-seronegative for AQP4-IgG and MOG-IgG (1126/1339; 84%), isolated MOG-IgA was identified in 3 of 50 patients (6%) with neuromyelitis optica spectrum disorder, 5 of 228 patients (2%) with other CNS demyelinating diseases, and 10 of 848 patients (1%) with multiple sclerosis but in none of the healthy controls (0/110). The most common disease manifestation in patients seropositive for isolated MOG-IgA was myelitis (11/17 [65%]), followed by more frequent brainstem syndrome (7/16 [44%] vs 14/75 [19%], respectively; P = .048), and infrequent manifestation of optic neuritis (4/15 [27%] vs 46/73 [63%], respectively; P = .02) vs patients with MOG-IgG. Among patients fulfilling 2017 McDonald criteria for multiple sclerosis, MOG-IgA was associated with less frequent CSF-specific oligoclonal bands (4/9 [44%] vs 325/351 [93%], respectively; P < .001) vs patients with multiple sclerosis who were MOG-IgG/IgA seronegative. Further, most patients with isolated MOG-IgA presented clinical attacks after recent infection or vaccination (7/11 [64%]). CONCLUSION AND RELEVANCE: In this study, MOG-specific IgA was identified in a subgroup of patients who were double-seronegative for AQP4-/MOG-IgG, suggesting that MOG-IgA may be a novel diagnostic biomarker for patients with CNS demyelination.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ayroza Galvão Ribeiro Gomes AB, Kulsvehagen L, Lipps P, et al. Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination. JAMA Neurol. 2023. PMID: 37548987. doi:10.1001/jamaneurol.2023.2523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。